The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK exec caught off-guard by China graft charges: sources

Thu, 15th May 2014 09:14

By Adam Jourdan and Kazunori Takada

SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be chargedwith leading a network of corruption in China's pharmaceuticalindustry, two sources with ties to the businessman and knowledgeof the investigation said.

The allegations against the Briton, who as GSK's China headwas the firm's legal representative in the country, are the mostserious charges ever laid against a foreign national forcorporate corruption in China, lawyers said.

Police said they had charged Reilly and two Chinesecolleagues with multiple offences on Wednesday, after a 10-monthprobe found the firm made billions of yuan from schemes to bribedoctors and hospitals.

"The fact that Mark's name was on the list of people chargedwas definitely a surprise," said a source with direct knowledgeof the investigation. The source declined to be named because ofthe sensitivity of the case.

Police findings are usually upheld in Chinese courts,meaning Reilly and the other executives could face decades injail.

GSK did not respond to requests for comment on Thursday.

Britain's biggest drugmaker said in a statement on Wednesdaythat the allegations were "deeply concerning" and it hoped to"reach a resolution" that would enable it to continue to operatein China, a key growth market for Western pharmaceutical giants.

Reilly, a scientist and accountant who has been with GSK forover two decades, briefly left China after the scandal broke inJuly last year. He voluntarily returned to assist authoritieswith the probe, with insiders saying the understanding was thiswould shield him from charges.

"I've had regular contact with Mark over the past fewmonths. I would think that this state of affairs is a surpriseto him. I don't think he is prepared, or thought that he couldbe culpable," an industry executive in China who has personalties to Reilly said.

Attempts to reach Reilly were unsuccessful.

NEXT STEPS

The last major corruption scandal to hit a foreign companyin China involved miner Rio Tinto in 2009,which resulted in four executives including a Chinese-bornAustralian being jailed for between seven and 14 years.

Reilly and two Chinese executives, Zhang Guowei and ZhaoHongyan, are charged with corporate bribery, bribingnon-government officials and bribing business units.

Officials gave no specific details on the amount of bribespaid or how much the company had illegally earned, althoughpreviously they accused the firm of funnelling up to 3 billionyuan ($482 million) to travel agencies to facilitate bribes todoctors and officials.

According to normal process, Reilly should have beendetained as soon as authorities laid charges against him.

Police could not be reached for comment and the Britishconsulate declined to comment on Reilly's whereabouts. Theindustry executive said he believed the Briton was still inShanghai.

Reilly had likely been barred from leaving China after hisreturn to help with the investigation, lawyers said.

WAKE-UP CALL

The prosecution will now examine the case before passing itto the courts, which could take as little as a month or muchlonger if further investigation is required, lawyers said.

GSK is the most prominent of a number of graft probes thathave been launched against global drug firms since last year,and authorities are unlikely to risk the investigation beingoverturned in the courts.

"For a sensitive and closely followed case like this, thepolice and prosecutors will have consulted with each otheralready," said Leon Liu, Shanghai-based partner at law firm MWEChina.

Chinese officials visited other international drugmakersincluding Novartis AG, AstraZeneca Plc, SanofiSA, Eli Lilly & C o and Bayer AG last year as part of a broad investigation into the sector,which is rife with bribery between sales staff and doctors.

Legal experts said the GSK case was a wake-up call toforeign companies that thought their top expatriate executiveswere immune from criminal charges as authorities step up acrackdown on corruption ordered by President Xi Jinping.

"There's a notion that only people of Chinese nationalityare going to go to jail here," said Steven Dickinson,Qingdao-based partner with law firm Harris Moure.

"People always say they'll never put a Briton or an Americanin jail. But they will, and this is just that example." (Additional reporting by John Ruwitch in SHANGHAI; Editing byStephen Coates)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.